Department of Renal Medicine, The Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.
Am J Kidney Dis. 2013 Dec;62(6):1095-101. doi: 10.1053/j.ajkd.2013.06.016. Epub 2013 Aug 16.
Accurate quantification of albuminuria is important in the diagnosis and management of chronic kidney disease. The reference test, a timed urinary albumin excretion, is cumbersome and prone to collection errors. Spot urine albumin-creatinine ratio (ACR) is convenient and commonly used, but random day-to-day variability in ACR measurements has not been assessed.
Prospective cohort study of day-to-day variability in spot urine ACR measurements.
SETTING & PARTICIPANTS: Clinically stable outpatients (N = 157) attending a university hospital clinic in Australia between July 2007 and April 2010.
Spot urine ACR variability was assessed and repeatability limits were determined using fractional polynomials.
ACRs were measured from spot urine samples collected at 9:00 am on consecutive days and 24-hour urine albuminuria was measured concurrently.
Paired ACRs were obtained from 157 patients (median age, 56 years; 60% men; median daily albumin excretion, 226 [range, 2.5-14,000] mg/d). Day-to-day variability was substantial and increased in absolute terms, but decreased in relative terms, with increasing baseline ACR. For patients with normoalbuminuria (ACR < 3 mg/mmol [<27 mg/g]), a change greater than ±467% (0-17 mg/mmol [0-150 mg/g]) is required to indicate a significant change in albuminuria status with 95% certainty; for those with microalbuminuria (ACR of 3-30 mg/mmol [27-265 mg/g]), a change of ±170% (0-27 mg/mmol [0-239 mg/g]) is required; for those with macroalbuminuria (ACR > 30 mg/mmol [>265 mg/g]), a change of ±83% (5-55 mg/mmol [44-486 mg/g]) is required; and for those with nephrotic-range proteinuria (ACR > 300 mg/mmol [>2,652 mg/g]), a change of ±48% (158-443 mg/mmol [1,397-3,916 mg/g]) is needed to represent a significant change.
These study results need to be replicated in other ethnic groups.
Changes in chronic kidney disease status attributed to therapy or disease progression, when based solely on a change in ACR, may be incorrect unless the potential for day-to-day biological variation has been considered. Only relatively large changes are likely to indicate a change in disease status.
准确量化白蛋白尿对于慢性肾脏病的诊断和治疗非常重要。参考测试是尿白蛋白排泄的定时测量,这种方法繁琐且容易出现收集错误。随机尿液白蛋白-肌酐比值(ACR)方便且常用,但尚未评估 ACR 测量的日常日间变异性。
对随机尿液 ACR 测量的日常日间变异性进行前瞻性队列研究。
2007 年 7 月至 2010 年 4 月期间,在澳大利亚一所大学医院诊所就诊的临床稳定门诊患者(N=157)。
使用分数多项式评估随机尿液 ACR 变异,并确定重复性限值。
在连续两天的上午 9 点采集随机尿液样本测量 ACR,并同时测量 24 小时尿白蛋白排泄量。
从 157 例患者中获得配对 ACR(中位年龄 56 岁;60%为男性;中位每日白蛋白排泄量 226 [范围,2.5-14,000]mg/d)。患者的日常日间变异性较大,绝对值增加,但随着基线 ACR 的增加,相对值降低。对于正常白蛋白尿(ACR<3mg/mmol [<27mg/g])患者,需要改变大于±467%(0-17mg/mmol [0-150mg/g])才能有 95%的把握表明白蛋白尿状态发生了显著变化;对于微量白蛋白尿(ACR 为 3-30mg/mmol [27-265mg/g])患者,需要改变±170%(0-27mg/mmol [0-239mg/g]);对于大量白蛋白尿(ACR>30mg/mmol [>265mg/g])患者,需要改变±83%(5-55mg/mmol [44-486mg/g]);对于肾病范围蛋白尿(ACR>300mg/mmol [>2652mg/g])患者,需要改变±48%(158-443mg/mmol [1,397-3,916mg/g])才能表示显著变化。
这些研究结果需要在其他种族群体中复制。
如果没有考虑到日常生物学变异性的潜在影响,仅基于 ACR 的变化,基于治疗或疾病进展的慢性肾脏病状态变化可能是不正确的。只有相对较大的变化才可能表明疾病状态的变化。